Eterna Therapeutics raises up to $7.3M in private placement; resets annual meeting to June 2

Ernexa Therapeutics Inc.

Initial closing on April 2: sold 9.93M shares and 509,736 pre-funded warrants for $1.1M.
Second closing of $6.2M (48.33M shares, 10.54M warrants) subject to stockholder approval by June 30 (or July 30 if SEC reviews).
Purchase price $0.1046 per share; pre-funded warrants at $0.0996 with $0.005 exercise price.
Investors include existing 32% holder Charles Cherington and former director Nicholas Singer.
2025 annual meeting moved to June 2; stockholder proposal deadline is April 13.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.